{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:11:10Z","timestamp":1791670270525,"version":"4.3.4"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec id=\"ab-doi230065-4\"><jats:title>Importance<\/jats:title><jats:p>Despite the US Food and Drug Administration\u2019s approval of adalimumab for the treatment of hidradenitis suppurativa (HS), prescription rates remain low, indicating a critical gap between evidence-based guidelines and clinical practice. Understanding the medical decision-making process that these patients use when considering biologic agents and other HS therapies may uncover opportunities for improved patient-physician communication and HS disease control.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230065-5\"><jats:title>Objective<\/jats:title><jats:p>To elucidate factors that affect the medical decision-making process for patients with HS, with an emphasis on biologic therapies.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230065-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>Open-ended semistructured interviews were conducted with English-speaking adults with HS (aged \u226518 years) recruited from 2 dermatology clinics that are part of Emory University School of Medicine in Atlanta, Georgia. All participants had an average 7-day pain score of 1 or higher on a 0- to 10-point numeric rating scale. Surveys were conducted between November 2019 and March 2020, and data were analyzed from December 2021 to August 2022. Data collection continued until thematic saturation was reached at 21 interviews.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230065-7\"><jats:title>Results<\/jats:title><jats:p>A total of 21 participants (median [IQR] age, 38.5 [27.9-43.4] years; 16 females [76%]) were included in the analysis. Almost all participants (96%) had Hurley stage II or III disease, and 15 (71%) had a history of adalimumab use. Suffering threshold, perceptions of treatment risk, treatment fatigue, disease understanding, and sources of information (included dermatologists, the internet, advertisements, and friends and loved ones) were identified as factors affecting participants\u2019 decisions to initiate new treatments for HS.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230065-8\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Results of this qualitative study suggest that mitigating misconceptions about treatment risk, identifying gaps in disease knowledge, and emphasizing early treatment to prevent scarring and disease progression may empower patients with HS to engage in treatment planning and to try new therapies.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.5425","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T16:00:53Z","timestamp":1704902453000},"page":"179","source":"Crossref","is-referenced-by-count":11,"title":["Factors Affecting Treatment Selection Among Patients With Hidradenitis Suppurativa"],"prefix":"10.1001","volume":"160","author":[{"given":"Nicole","family":"Salame","sequence":"first","affiliation":[{"name":"Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacine N.","family":"Sow","sequence":"additional","affiliation":[{"name":"Morehouse School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meron R.","family":"Siira","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, New Hyde Park, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suephy C.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Patzer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dio","family":"Kavalieratos","sequence":"additional","affiliation":[{"name":"Division of Palliative Medicine, Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A. V.","family":"Orenstein","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"doi230065r1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jaad.2006.08.061","article-title":"Quality of life impairment in hidradenitis suppurativa: a study of 61 cases.","volume":"56","author":"Wolkenstein","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"doi230065r2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11916-017-0647-3","article-title":"Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa [corrected].","volume":"21","author":"Patel","year":"2017","journal-title":"Curr Pain Headache Rep"},{"issue":"6","key":"doi230065r3","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jaad.2017.07.027","article-title":"Uncovering burden disparity: a comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa.","volume":"77","author":"Hamzavi","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi230065r4","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","article-title":"Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.","volume":"86","author":"Garg","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi230065r5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000503605","article-title":"A comparison of international management guidelines for hidradenitis suppurativa.","volume":"237","author":"Hendricks","year":"2021","journal-title":"Dermatology"},{"issue":"5","key":"doi230065r6","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jaad.2020.07.108","article-title":"Low prescription of tumor necrosis alpha inhibitors in hidradenitis suppurativa: a cross-sectional analysis.","volume":"84","author":"Orenstein","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi230065r7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/bjd\/ljac018","article-title":"Pain experiences among those living with hidradenitis suppurativa: a qualitative study.","volume":"188","author":"Orenstein","year":"2023","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi230065r8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000526069","article-title":"Demographic gaps and requirements for participation: a systematic review of clinical trial designs in hidradenitis suppurativa.","volume":"239","author":"James","year":"2023","journal-title":"Dermatology"},{"issue":"1","key":"doi230065r9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000504911","article-title":"Race and ethnicity gaps in global hidradenitis suppurativa clinical trials.","volume":"237","author":"Price","year":"2021","journal-title":"Dermatology"},{"issue":"8","key":"doi230065r10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","article-title":"Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States.","volume":"153","author":"Garg","year":"2017","journal-title":"JAMA Dermatol"},{"key":"doi230065r11","author":"Sow","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi230065r12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1179\/108331905X55776","article-title":"Visual analogue scale, numeric pain rating scale and the McGill Pain Questionnaire: an overview of psychometric properties.","volume":"10","author":"Kahl","year":"2005","journal-title":"Phys Ther Rev"},{"issue":"2","key":"doi230065r13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/120347540100500202","article-title":"Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases.","volume":"5","author":"Chren","year":"2001","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"doi230065r14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/ced.1994.19.issue-3","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"doi230065r15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"10","key":"doi230065r16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7.","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"issue":"5","key":"doi230065r18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1159\/000507323","article-title":"Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice.","volume":"236","author":"Orenstein","year":"2020","journal-title":"Dermatology"},{"issue":"5","key":"doi230065r19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa.","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"doi230065r20","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"4","key":"doi230065r21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease.","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"doi230065r23","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/bjd.v185.5","article-title":"Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review.","volume":"185","author":"Howells","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi230065r26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.v184.1","article-title":"Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.","volume":"184","author":"Marzano","year":"2021","journal-title":"Br J Dermatol"},{"key":"doi230065r27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0001-7310(17)30007-8","article-title":"Management of patients with hidradenitis suppurativa.","volume":"107","author":"Martorell","year":"2016","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"doi230065r28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey of Impact and Healthcare Needs (VOICE) project.","volume":"82","author":"Garg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"doi230065r29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/ajes.v77.3-4","article-title":"Racial disparities in health status and access to healthcare: the continuation of inequality in the United States due to structural racism.","volume":"77","author":"Yearby","year":"2018","journal-title":"Am J Econ Sociol"},{"key":"doi230065r30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2147\/CCID","article-title":"Perspectives on perceived stigma and self-stigma in patients with hidradentis suppurativa.","volume":"12","author":"Koumaki","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"doi230065r31","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/bjd.v184.3","article-title":"Hidradenitis suppurativa and perceived stigmatization in a diverse Canadian clinic population: a pilot study.","volume":"184","author":"Bouazzi","year":"2021","journal-title":"Br J Dermatol"},{"key":"doi230065r17","author":"Hurley","year":"1996"},{"key":"doi230065r22","volume-title":"Qualitative Methods for Health Research","author":"Green","year":"2004","edition":"2nd ed"},{"key":"doi230065r24","unstructured":"Foundation? HS. Accessed December 6, 2023. https:\/\/www.hs-foundation.org"},{"key":"doi230065r25","unstructured":"Infor? MED. Welcome to the hidradenitis suppurativa decision aid. Accessed December 6, 2023. https:\/\/www.informed-decisions.org\/hidradenitispda.php"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2813822\/jamadermatology_salame_2024_oi_230065_1707346929.5228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T16:02:01Z","timestamp":1708531321000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2813822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.5425","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}